Solutions for SARS-CoV-2 Detection
We are here to help laboratories overcome their SARS-CoV-2 testing challenges so they can better address the world’s urgent public health concerns. We are working closely with laboratories around the world to deliver the nucleic acid isolation, automation, real-time PCR, antibody testing, and vaccine development solutions they need to rapidly respond to these challenges. Our top priority is to provide the technology and support to meet these needs.
Explore our SARS-CoV-2 Testing Products
Detect and differentiate SARS-CoV-2, influenza A, influenza B, and RSV in a single sample with the CE-IVD marked PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel. This workflow enables labs to conserve resources while testing a single sample for multiple pathogens.
The PerkinElmer New Coronavirus Nucleic Acid Detection Kit the most sensitive commercially available real-time RT-PCR kit authorized under FDA EUA for the detection of COVID-19 in human oropharyngeal, nasopharyngeal, and anterior nasal swab samples. It is now authorized for use with asymptomatic pooled samples.
The PerkinElmer® GSP®/DELFIA® Anti-SARS-CoV-2 IgG kit delivers qualitative detection of human IgG antibodies against SARS-CoV-2 in dried blood spots (DBS), plasma, and serum to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Automated, high-throughput processing of DBS is available with the GSP® instrument.
Manual processing of plasma and serum samples is available with the VICTOR2™ D instrument.
The SuperFlex™ Anti-SARS-CoV-2 kit delivers fast, hands-free anti-SARS-CoV-2 IgG antibody detection using direct chemiluminescence technology. Up to 12 samples can be run in 15 minutes to quickly identify recent or prior infections.
Automated on the SuperFlex™ Chemiluminescent Immunoassay Instrument up to 48 samples can be processed per hour.
The complete package for SARS-CoV-2 virus and antibody detection.
Improve the Efficiency of Coronavirus Testing
This is a challenging time for laboratories working on the front lines of COVID-19 pandemic. In this webinar, we will describe how PerkinElmer is helping the community address this urgent public health concern. We will share details on immediately deployable solutions that can equip labs with viral nucleic acid isolation set up, extraction and detection to efficiently process thousands of tests every day.
Read our blog post to learn about CoronaLab, a business unit of Microbe&Lab B.V., which provides cutting-edge SARS-CoV-2 RT-PCR testing for non-symptomatic people.Read More
SARS-CoV-2 testing is used for different applications including diagnostics, screening, and surveillance. Read our blog to learn more.Read More
Read our COVID-19 blog post to learn more about the COVID-19 B.1.1.7 and B.1.351 lineages of SARS-CoV-2 and find out if your RT-PCR assay can detect them.Read More
The onslaught of COVID-19 testing has led to burnout among lab employees. Read how labs can decrease their labor demands.Read More
Organizations have been exploring pooling of samples when performing SARS-CoV-2 testing to increase testing throughput and decrease cost. Because it allows for more people to be tested quickly using fewer testing resources, sample pooling is an important tool to help control the spread of SARS-CoV-2.Read More
Dr. Elizabeth Hillebrenner, associate director for scientific and regulatory programs at the FDA’s Center for Devices and Radiological Health, kicked off this virtual roundtable with an overview of the EUA program, how it evolved, and how lessons learned during the current pandemic may shape future policies and actions by the FDA. She then took part in a panel discussion that included a variety of stakeholders from the diagnostics and clinical lab industries.Read More
The FDA has authorized a new sample type, anterior nasal swabs, for use with some EUA authorized real-time RT-PCE assays for COVID-19 testing. Using anterior nasal swabs for SARS-CoV-2 testing offers many advantages over the typical sample types, human oropharyngeal and nasopharyngeal swab samples.Read More
On December 31, 2019, a pneumonia case in the Chinese city, Wuhan, with unknown pathological origin, was reported into the Chinese World Health Organization (WHO) office. By March 11, 2020, the virus had spread to 114 countries and had taken nearly 4,300 lives leading WHO to declare COVID-19 a global pandemic (WHO, 2020).Read More
SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) tests, can be inaccurate in two ways, as can all diagnostic assays. A false-positive result mistakenly identifies a person as infected, resulting in unnecessary quarantine and contact tracing. False-negative results are far more problematic because infected people may not isolate themselves and can infect others.Read More
Accurate detection of SARS-CoV-2 is critical for both patient treatments, as well as control of the COVID-19 pandemic. Many factors need to be considered when choosing a workflow to use for SARS-CoV-2 detection.Read More
Accuracy of SARS-CoV-2 testing is critical when determining if someone is infected and needs to be quarantined and/or treated for a coronavirus infection. Real-time reverse transcription polymerase chain reaction (RT-PCR) assays are the tool of choice for determining if someone has an active viral shedding of SARS-CoV-2. RT-PCR assays reverse transcribe the viral RNA into DNA for amplification and subsequent identification of target regions.Read More
Severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus responsible for the disease known as COVID-19, is now a global pandemic. This novel coronavirus was first observed in humans in December of 2019 and sequenced by multiple teams over the next month (Wu et al., 2020; Zhu et al., 2020; Chan et al., 2020).Read More
The CDC limits IRR’s SARS-CoV-2 diagnostic reagent distribution to US state and/or local labs qualified to perform seasonal influenza surveillance testing and to local labs approved by their state public health laboratory to perform SARS-CoV-2 testing. Only CLIA facilities with appropriate equipment, training, and demonstration of testing proficiency can be considered.Read More
PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 23, 2021-- PerkinElmer, Inc. (NYSE: PKI) today announced the launch of the PerkinElmer® COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or nasopharyngeal (NP) swab specimens.Read More
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 14, 2021-- PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to test individuals without symptoms or other reasons to suspect COVID-19 infection.Read More
WALTHAM, Mass. – December 16, 2020 – EUROIMMUN, a PerkinElmer, Inc. Company, today announced the launch of the CE marked SARS-CoV-2 Antigen ELISA for specific determination of the SARS-CoV-2 protein. The assay adds to the Company’s broad product portfolio for COVID-19 diagnostics and supports the molecular PCR tests to aid in diagnosing acute SARS-CoV-2 infections.Read More
WALTHAM, Mass. – December 14, 2020 – EUROIMMUN, a PerkinElmer, Inc. Company, today announced the launch of the CE marked EURORealTime SARS-CoV-2/Influenza A/B for direct detection of SARS-CoV-2, influenza virus type A and influenza virus type B. It expands the testing portfolio for acute COVID-19 diagnostics by supporting differential diagnostics between SARS-CoV-2 infections and the common flu. It is available in countries accepting the CE mark.Read More
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 12, 2020-- PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five specimens collected from individuals suspected of COVID-19 or asymptomatic individuals.Read More
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 9, 2020-- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1 antigen.Read More
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 29, 2020-- PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer® New Coronavirus Nucleic Acid Detection Kit to increase the number of individuals who can be tested without increasing resources.Read More
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 26, 2020-- PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD).Read More
WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 21, 2020-- PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day.Read More
Sonora Quest Collaborates with State and Health Care Leaders to Vastly Expand COVID-19 Testing Capacity in Arizona
July 9, 2020 PHOENIX — Governor Doug Ducey announced today a strategic collaboration with Sonora Quest Laboratories, the market share leader in diagnostics laboratory testing in Arizona, the Arizona Department of Health Services (ADHS) and PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, to expand testing in Arizona. The collaboration helps catapult COVID-19 diagnostic testing capacity well ahead of the significant demand in Arizona.Read More
An advanced laboratory dedicated to leading Wales’ national Covid-19 testing has been established in Cardiff, thanks to collaboration between Public Health Wales and one of the world’s leading diagnostics companies.Read More
WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 24, 2020-- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the Company’s New Coronavirus RT-PCR test.Read More
EUROIMMUN is one of first European manufacturers of diagnostic testing to provide CE-marked antibody detection systems to support COVID-19 diagnostics
The Anti-SARS-CoV-2 ELISAs for immunoglobulin classes A and G from EUROIMMUN, a PerkinElmer, Inc. company (NYSE:PKI), have received the CE mark and can now be applied to COVID-19 diagnostics. The PCR test EURORealTime SARS-CoV-2 has been submitted for CE mark.Read More
FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies
WALTHAM, Mass.--(BUSINESS WIRE)--May 5, 2020-- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test.Read More